Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Baudax Bio Inc (NQ: BXRX )

0.3490 +0.0040 (+1.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Baudax Bio Inc

Watchlist Alert: Nasdaq Stocks Under $1 Experience Volume Breakouts: KAVL, BXRX, RMED, SMX
Via AB Newswire
Baudax Bio Reports First Quarter Financial Results and Provides Business Update
From Baudax Bio, Inc.
Via GlobeNewswire
Baudax Bio to Present at the Sidoti Virtual Investor Conference
From Baudax Bio, Inc.
Via GlobeNewswire
Baudax Bio Announces Closing of $4 Million Public Offering
From Baudax Bio, Inc.
Via GlobeNewswire
Baudax Bio Announces Pricing of $4 Million Public Offering
From Baudax Bio, Inc.
Via GlobeNewswire
Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000
From Baudax Bio, Inc.
Via GlobeNewswire
Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial
Virtual Webinar to be held April 25, 2023 at 10:00 AM Eastern Time 
From Baudax Bio, Inc.
Via GlobeNewswire
Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000
From Baudax Bio, Inc.
Via GlobeNewswire
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update
From Baudax Bio, Inc.
Via GlobeNewswire
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. 
Via MarketBeat
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000
From Baudax Bio, Inc.
Via GlobeNewswire
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030
EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END 
Via FinancialNewsMedia
Baudax Bio (NASDAQ: BXRX) Launches Phase 2 Clinical Trial Testing BX1000 for Neuromuscular Blockade in Patients Undergoing Surgery
Baudax Bio, Inc. (NASDAQ: BXRX) is engaged as a pharmaceutical company, which is focused on developing innovative products for use 
Via Spotlight Growth
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
From Baudax Bio, Inc.
Via GlobeNewswire
Baudax Bio Announces Closing of $5 Million Public Offering
From Baudax Bio, Inc.
Via GlobeNewswire
Baudax Bio Announces Pricing of $5 Million Public Offering
From Baudax Bio, Inc.
Via GlobeNewswire
Baudax Bio Announces 1-for-40 Reverse Stock Split
From Baudax Bio, Inc.
Via GlobeNewswire
Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights
From Baudax Bio, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.